Patent information analysis of TCM prescription for the treatment of diabetes based on patent analysis and SWOT model by Lulu Ni, Xu Chen, Xu Gong, Min Ai, Mengrui Xiong, Xuyi Tao, Yufei Hu, Jiangan Li, Sujuan Zhang

“…Three typical domestic pharmaceutical companies (Hebei Yiling Pharmaceutical, Tianjin Tianshili Pharmaceutical and Lunan Pharmaceutical Group) have their own characteristics in the field of technological innovation and patent layout in the treatment of diabetes, but there is a defect of insufficient power of original technology. …”
Get full text

Microfluidics for 3D Cell and Tissue Cultures: Microfabricative and Ethical Aspects Updates by Tania Limongi, Francesco Guzzi, Elvira Parrotta, Patrizio Candeloro, Stefania Scalise, Valeria Lucchino, Francesco Gentile, Luca Tirinato, Maria Laura Coluccio, Bruno Torre, Marco Allione, Monica Marini, Francesca Susa, Enzo Di Fabrizio, Giovanni Cuda, Gerardo Perozziello

“…The necessity to improve in vitro cell screening assays is becoming ever more important. Pharmaceutical companies, research laboratories and hospitals require technologies that help to speed up conventional screening and therapeutic procedures to produce more data in a short time in a realistic and reliable manner. …”
Get full text

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes by Naim Alkhouri, Fred Poordad, Eric Lawitz

“…However, the field of drug development in NAFLD has witnessed a revolution over the past 5 years with the establishment of a regulatory pathway for Food and Drug Administration approval; this has generated substantial interest from pharmaceutical companies. Several diabetes medications have been studied as potential treatments for NAFLD with promising results; moreover, drugs that target specific pathways that play a role in NAFLD development and progression are being developed at a rapid pace. …”
Get full text

Communicating the “Race” for the COVID-19 Vaccine: An Exploratory Study in Newspapers in the United States, the United Kingdom, and Brazil by Luisa Massarani, Luiz Felipe Fernandes Neves

“…The search for an effective solution to control the COVID-19 pandemic has mobilized an unprecedented effort by science to develop a vaccine against the disease, in which pharmaceutical companies and scientific institutions from several countries participate. …”
Get full text

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment by Yewon Park, Joo Young Na, Joo-Youn Cho, Jaeseong Oh, Su-jin Rhee

“…Time to recovery is the primary endpoint associated with clinical efficacy and is generally well accepted by many experts.Conclusion: Through this suggested phase 2 or 3 study design of an anti-inflammatory drug for COVID-19, we provide a basis for a study design that can be utilized in clinical development by pharmaceutical companies which are developing a potential anti-inflammatory agent for COVID-19.…”
Get full text

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies by Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Özkazanc, Lucia Kučerová, Adil Doganay Duru, Jan Spanholtz, Monica Raimo

“…This review offers a comprehensive overview of the effort driven by biotech and pharmaceutical companies and by academic centers to bring NK cell therapies to pivotal clinical trial stages and to market authorization.…”
Get full text

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses by Prokofjeva Maria M, Riecken Kristoffer, Spirin Pavel V, Yanvarév Dimitriy V, Düsedau Arne, Ellinger Bernhard, Fehse Boris, Stocking Carol, Prassolov Vladimir S

“…This allowed upscaling to a large-scale screening protocol exploited by pharmaceutical companies in a successful proof-of-concept experiment.…”
Get full text

Safety and efficacy of drugs: What do I need to know? by Mahmoud Hadipour Dehshal

“…Furthermore, in the lecture, we aim to reflect over the role of different beneficiaries including international organizations, governments, and pharmaceutical companies in ensuring the feasible and sustainable access of citizens to the essential medicines.…”
Get full text

Psychotropic drugs in Nepal: perceptions on use and supply chain management by Nawaraj Upadhaya, Mark J. D. Jordans, Dristy Gurung, Ruja Pokhrel, Ramesh P. Adhikari, Ivan H. Komproe

“…Conclusions The production and supply chain management of psychotropic drugs is influenced by the vested interests of pharmaceutical companies, prescribers and pharmacists. In the context of the government of Nepal’s policy of integrating mental health into primary health care and increased consumption of psychotropic drugs in Nepal, there is a need for massive education and awareness as well as strict monitoring and supervision to avoid the misuse of psychotropic drugs.…”
Get full text

Ecopharmacognosy: Exploring The Chemical And Biological Potential Of Nature For Human Health by Geoffrey A. Cordell

“…Significantly, pharmaceutical companies have retrenched substantially in their disease areas of focus.  …”
Get full text

Antibiotic prescribing in two private sector hospitals; one teaching and one non-teaching: A cross-sectional study in Ujjain, India by Sharma Megha, Eriksson Bo, Marrone Gaetano, Dhaneria Suryaprakash, Lundborg Cecilia

“…High use of combinations of antibiotics in the NTH might indicate pressure from pharmaceutical companies. There is a need to formulate and implement; based on local prescribing and resistance data; contextually appropriate antibiotic prescribing guidelines and a local antibiotic stewardship program.…”
Get full text

Characteristics of criminal cases against physicians charged with opioid-related offenses reported in the US news media, 1995–2019 by Julia B. Berman, Guohua Li

“…Abstract Background Pharmaceutical companies and drug distributors are intensely scrutinized in numerous lawsuits for their role in instigating the opioid epidemic. …”
Get full text

Treatment and disposal practices of pharmaceutical effluent containing potential antibiotic residues in two states in India and perceptions of various stakeholders on contribution... by Anita Kotwani, Ajita Kapur, Mihir Chauhan, Sumanth Gandra

“…Results The effluent treatment and disposal practices varied with the multinational companies (MNCs) having advanced technologies whereas the small and medium-scale pharmaceutical companies (SMPCs) having effluent treatment plants as per the regulations but often under-utilized. …”
Get full text

Rate Setting for Labour Costs Related to Pharmacovigilance System Inspections by M. Abdrakhmanov, R. N. Alyautdin, A. E. Krasheninnikov, B. K. Romanov

“…A constructive discussion of approaches to the improvement of control over pharmacovigilance systems will increase availability of efficacious and safe medicines of assured quality for the population and help pharmaceutical companies and regulatory authorities manage financial and reputational risks.…”
Get full text

An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims by Chatterjee S, Patel HK, Sansgiry SS

“…Economic claims included any form of claim made on behalf of the pharmaceutical companies related to cost superiority of or cost savings from the drug compared to other drugs in the market.Results: In the 6-year study period, 65 warning letters were issued by FDA, which contained 144 clinical, three QoL, and one economic claim. …”
Get full text

جودة المعلومات وأثرها في تحقيق المرونة الاستراتيجية دراسة ميدانية في )شركات صناعة الأدوية الأردنية(... by فايز جمعـه النجـار, فالح عبد القادر الحوري

“…The study subjects have consisted of all administrative directors in the pharmaceutical companies registered in Amman Stock Exchange (the first and second markets). …”
Get full text

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA) by Yuriko Terayama, Noriko Tomita, Junko Terada-Hirashima, Yukari Uemura, Yosuke Shimizu, Junko S. Takeuchi, Yuki Takamatsu, Kenji Maeda, Ayako Mikami, Mugen Ujiie, Wataru Sugiura

“…However, the neutralizing antibody titers in vaccinated individuals are reported to progressively decrease over time. Japanese pharmaceutical companies have published the results of Phase I and II studies on the safety and efficacy of different vaccines. …”
Get full text

Promotion of prescription drugs to consumers and providers, 2001-2010. by Rachel Kornfield, Julie Donohue, Ernst R Berndt, G Caleb Alexander

“…Little change occurred in the composition of promotion between primary care physicians and specialists from 2001-2010.These findings suggest that pharmaceutical companies have reduced promotion following changes in the pharmaceutical pipeline and patent expiry for several blockbuster drugs. …”
Get full text

A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full by Thomas Brenda M, Brazzelli Miriam, Gibson Lorna M, Sandercock Peter AG

“…Responsibility for non-publication lies with investigators, but pharmaceutical companies, research ethics committees, journals and governments can all encourage the timely publication of trial data.…”
Get full text

Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences by Abouarab, Bechara, Bazarian, Christian, Ben Chaouch, Zied, Lo, Andrew W., Mourenza Gonzalez, Guillermo, Novak, Richard, Vigneault, Frederic

“…Conclusions Repurposing existing compounds offers important advantages that could help early-stage biotech startups better align their business and financing issues with their scientific and medical objectives, enter a space that is not occupied by large pharmaceutical companies, and accelerate the validation of their drug development platform.…”
Get full text